David Buswell CEO Immune Response Biopharma responds to questions

Below is Mr. Buswell's reply to my letter.



From David Buswell, CEO Immune Response BioPharma

GOTO HELL

---

From: Joel Reese
Sent: Tuesday, June 18, 2013 1:57 PM
To: David Buswell
Subject: Investment with Immune Response BioPharma

 

Dear Mr. Buswell:   I am very impressed with the description of Immune Response BioPharma on your company's website. It seems you have a number of drugs in development any one of which would be of great benefit to those who suffer from these terrible diseases. If just one of these drugs should gain approval Immune Response BioPharma could become profitable in a very short time.   I am also aware that your company is attempting to use research from the Immune Response/Orchestra Corporation in an attempt to raise funding for Immune Response BioPharma. As a long time investor in IMNR/OCHT still holding 64,483 shares I wish to advise you that the research was not abandoned by its investors and I feel that illegal manipulation of the IMNR/OCHT stock and ownership was used to basically steal its research and cheat its creditors in an attempt to create what you now call Immune Response Biophama. Your company boasts a great deal of what the legality of what it is doing, but I say to you that it is immoral, unfair, and unwise to simply abandon the stock holders who financed the research you now claim to own without offering to make their stock holdings now part of the new company or offering them fair payment for their stock. I don't know what if anything the owners of IMNR/OCHT stock can do at this point legally to protect their rights, but I can assure you that I will make every effort to see that I am not cheated and to let other potential investors of yours know of your company's history and connection to IMNR/OCHT to prevent what happened to us from happening to them. There is such a thing as right and wrong and what you are attempting to do is clearly wrong. I am writing to inquire if Kevin Kimberlin who purchased property rights to research at IMNR/OCHT through Spencer Trask is involved in the Immune Response BioPharma Corporation and what his role is? I am sure that  Spencer Trask, David Buswell, and Immune Response BioPharma wish to be honorable in how they handle this and treat the investors of IMNR fairly. Thank you for your consideration and assistance.

Immune Response Incorporated

The message board for Orchestra on yahoo is still active under OCHTQ. There doesn't seem to be much progress being made for Immune Response Biopharma other than changes on their website.

Immune Response, Orchestra, and Immune Response Biophrama

Immune Response BioPharma has issued a press release (Jan. 7, 2013) citing its 2012 highlights and its goals for 2013. The Immune Response Corp began originally under Dr. Jonas Salk in 1986-87 seeking a vaccine to treat HIV. By April, 1990 the biotechnology company had filed to hold a 2.2-million share initial public stock offering that was expected to raise as much as 19.8 million. By September, 1991, Immune Response was the hottest biotechnology issue on the market with shares climbing from a January 1991 price of $2.875 to $32.625 in over-the-counter trading based on its HIV therapeutic vaccine which was said to be in the advanced stages of clinical trails. In 1998 Immune Response signed a deal with Agouron Pharmaceuticals Inc. a unit of Pfizer as a developing and marketing pact for its AIDS drug.

The problem was that the test results were either disappointing or were challenged as being poorly designed and therefore unreliable. By July 7, 2001 shares of Immune Response plunged 44% after Pfizer discontinued development of the drug and ended its association with Immune. By September 2002, Dennis Carlo, the companies CEO had resigned and the company was forced to cut half its staff. The company's auditors publicly questioned the ability of Immune Response to continue to operate. Despite years and years of testing and research the company was still unable to prove that Remune, the vaccine it developed to treat HIV, was effective. In March of 2007 the company had moved on and was injecting its first patient in a large multi-center Phase II study of NeuroVax(TM) its multiple sclerosis vaccine. NeuroVax(TM) was based on the company's patented T-cell receptor peptide vaccine technology.

By October 2008 the company had filed for bankruptcy. At the time the company listed $32.61 million in liabilities and $1.64 million in assets. Now, in 2013, nearly 27 years after Dr. Salk first founded the company Immune Response continues trying to prove the value of Remune and NeuroVax as well as other vaccines developed by the company years ago. It claims to to have plans to partner with large pharma partners and to be on track for record growth and profits in the future. Financing for the company for now remains a mystery as does the results of any recent studies.

Immune Response and 2013

I just wanted to thank the many people around the world who have visited and viewed my blog over the past year. Looking toward 2013 I will continue to work on behalf of my fellow investors in Immune Response/Orchestra Therapeutics and seek to protect our rights concerning Immune Response Biopharma. The research they now seek to exploit was financed and supported for nearly twenty years by investors including myself. Though they claim to be a new and separate company all their research was in fact conducted and financed more than ten years ago. Hopefully investors like myself will be able to convince Immune Response Biopharma to deal fairly with the original investors.

Immune Response BioPharma and Immune Response Corp. research.

The present company of Immune Response Biopharma which is really just the old Immune Response Incorporated or Orchestra Therapeutics has a really impressive website. It shows that the current incarnation of Immune Response/Orchestra is called the Immune Response BioPharma and seems to be made of people and research the company had nearly 15 years ago. Dr. Richard Bartholomew and Dr. Arthur Vandenbard, all go back into the 90s with Immune Response Inc.  The research they are now touting is actually research conducted nearly 15 years ago. Their recent press release on REMUNE, Oct. 31, 1912, sites Study 806 which was terminated in 1999. Its hard to believe that people would invest in clinical test results that old which were conducted by a company that then went Chapter 11 defrauding both their creditors and investors out of all their money. The website seems to be designed to lure unsuspecting investors and supporters. I along with most others who invested in this research lost all my money and ended up bankrupt with nothing. I just hope the same thing doesn't happen again to investors.

Immune Response

Over 2,500 people have viewed this blog since it was first created. Seems a lot of people are interested in the connection between Immune Response/Orchestra and Immune Response BioPharma.

David Buswell and Dennis Carlo

The annoucement by David Buswell that Immune Response BioPharma was being dumped by GSK sounds just like the sort of statements that Dennis Carlo, former president and CEO of Immune Response used to put out. I wonder if they are one and the same person. The two companies seem to be one and the same. Hard to imagine there could be two CEOs who would issue statements like this.

May 24, 2012.
"Immune Response BioPharma, Inc. has the first MS Vaccine a first in class and best in class multiple sclerosis drug which restores deficient FOXP3+ T-Regs. GSK has no approved MS drug and probably will never have one they are busy wasting their shareholders money on HGSI and a Lupus drug with poor sales, we don't need them or to give away our blockbuster drug for MS to them which we believe will become treatment of choice" IRBP CEO Mr. Buswell

"IRBP values NeuroVax north of a billion dollar of annual sales once approved. We will find a solid partner or raise capital on our own, we don't need GSK which has zer0 experience in multiple sclerosis or auto-immune diseases. GSK is a joke and seems very ignorant on how multiple sclerosis drugs work and how to develop one, we gave them a chance to develop NeuroVax but their management appears to be very poor. We have decided to terminate any collaboration or development with GSK. GSK is a loser in the MS market and will continue to be a loser" IRBP CEO Mr. Buswell

Open Letter to Immune Response BioPharma

Immune Response BioPharma, Inc.

244 5^th Avenue Suite 1727

New York City, NY

10001

Dear Sir or Madam:

I am writing to seek information on Immune Response Biopharma’s use of research belonging to Immune Response Inc/Orchestra Therapeutics. I spoke recently to a representative at Spencer Trask who informed me that neither Kevin Kimberlin nor Spencer Trask had any connection whatsoever to the new Immune Response BioPharma. He also stated that Kevin Kimberlin had purchased the intellectual property rights to the research at Immune Response/Orchestra at a public auction after the company went through Chapter 7 bankruptcy.

Records show though that Kevin Kimberlin through Spencer Trask went from owning approximately 2 million shares of common stock to eventually acquiring a total of 4.4 million shares. His shares along with those of others like Michael Green, Georgia Theofan, Richard Bartholomew, and other members of the Board of Directors would have owned a majority of the company’s 10 million shares. He continually provided financing for Orchestra in return for intellectual property rights as he took the company into bankruptcy according to SEC filings. He also received a security interest in all the assets of the company.

I have several questions which I want answers to. Was the intellectual property rights exempted from the assets of the company in the bankruptcy proceedings? What became of the companies brand new state of the art manufacturing plant in King of Prussia? It was up for sale, but I have never seen anything on the final sale or purchase. Does Immune Response Biopharma now own this facility?

As of February 2012 the bankruptcy proceedings are still pending.

Orchestra Therapeutics, Inc. (CIK No. 817785) is a void Delaware corporation located in Carlsbad, California with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). Orchestra is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-Q/A for the period ended June 30, 2007, which reported a net loss of over $3.9 million for the prior six months. On October 13, 2008, the company filed a Chapter 7 petition in the U.S. Bankruptcy Court for the Southern District of California, and the case was pending as of February 16, 2012. As of April 30, 2012, the company’s stock (symbol “OCHTQ”) was quoted on OTC Link, had ten market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

How can Immune Response Biopharma claim the research was abandoned when it was being purchased by Kevin Kimberlin both before the company went Chapter 7 through SEC filings and after through a public auction. David Buswell claims that the research was abandoned. Why would Kimberlin invest 20 years and a total 350 million in these drugs and purchase its research both before and after the Chapter 7 and then abandon the research?

If your company has sound legal status and rights to the research you should be able to offer answers to these questions which myself and other stock holders of Orchestra Therapeutic Inc/Immune Response have.

The Orchestra/Immune Response Chapter 7 still seems to be ongoing and not complete as of June 2012.

2. Orchestra Therapeutics, Inc. (CIK No. 817785) is a void Delaware corporation located in Carlsbad, California with a class of securities registered with the Commission pursuant to Exchange Act Section 12(g). Orchestra is delinquent in its periodic filings with the Commission, having not filed any periodic reports since it filed a Form 10-Q/A for the period ended June 30, 2007, which reported a net loss of over $3.9 million for the prior six months. On October 13, 2008, the company filed a Chapter 7 petition in the U.S. Bankruptcy Court for the Southern District of California, and the case was pending as of February 16, 2012. As of April 30, 2012, the company’s stock (symbol “OCHTQ”) was quoted on OTC Link, had ten market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

Spencer Trask and Immune Response Biopharma

I have been writing letters to the Spencer Trask group for the past few months asking if they or their associate Kevin Kimberlin were in any way connected to the new company calling itself Immune Response Biopharma. I finally received a call back from New York today from a Spencer Trask representive. He stated plainly that there was no connection between Spencer Trask or Kevin Kimberlin and the new Immune Response Biopharma. He also stated that Kevin Kimberlin purchased the research to the original Immune Response/Orchestra Therapeutic company at a public auction that occured after the company went through bankruptcy and not before. Apparently the news releases put out by Orchestra about Kevin Kimberlin and Spencer Trask providing operational financing for Orchestra in return for intellectual property rights during the last two years of the companies operation were incorrect. The gentlemen I spoke with said that the new company had no connection to Immune Response/Orchestra other than the fact that the new company chose to use a similar name. Basically the new Immune Response Biopharma company under David Buswell is "NOT" using the research from Immune Response/Orchestra nor did they obtain the intellectual property rights from Immune Response/Orchestra as those were purchased by Kevin Kimberlin as part of the settlement of the companies holdings after the bankruptcy hearings. Anyone else have any information or comments to ad?

Legal Contacts concerning rights of Immune Response Inc and Biopharma

Investors of Immune Response/Orchestra might want to also contact the following:
United States Trustee
United States Department of Justice
402 West Broadway, Suite 600
San Diego, CA
92101
Chief, Special Procedures
Section - Insolvency
Internal Revenue Service
P.O. Box 30213
Laguna Niguel, CA
92607-0213
United States Securities and Exchange Commission
5670 Wilshire Blvd, 11th Floor
Los Angeles, California
90036
U.S. Bankruptcy Court
Southern District of California
325 West F Street
San Diego, CA
92101
(619) 557-5620

Investigation of Immune Response Biopharma

Investors of Immune Response Inc. / Orchestra Therapeutics Inc. who have concerns about the activities of Immune Response Biopharma Inc. might wish to contact the following to request an investigation of this new company to see if they are in fact the old company with a slight change in name. The name is almost the same as the original Immune Response, the research is the same research, and many of the people now running the company are the same people.

Perhaps investors need to write and contact the following in order to protect their rights.

The new Immune Response Biopharma is taking the research from Immune Response Inc. and seeking FDA approval.

Food and Drug Administration

10903 New Hampshire Ave
Silver Spring, MD 20993-0002

or by telephone:

• 1-888-INFO-FDA (1-888-463-6332)—main FDA Phone Number (for general inquiries)
• Electronic Employee Directory¹
• FDA Public Affairs Specialists²

Freedom of Information: FDA cannot accept on-line Freedom of Information Act requests (because such requests must be signed in writing); however, information about filing such requests is available in FDA's Electronic FOI Reading Room³.

The original Immune Response Inc. later became Orchestra Therapeutics and filed bankruptcy immediately thereafter. During the last few months after the name change one of the companies founders, Kevin Kimberlin and the Spencer Trask organization purchased all the intellectual property rights for the research from the company. The new Immune Response Biopharma says they then abandoned those rights immediately after that.

One can't help but feel the whole thing sounds fishy. Original investors might want to contact the courts that handled the original Chapter 7 was filed.

United States Bankruptcy Court
for the
Southern District of California
Jacob Weinberger United States Courthouse

325 West F Street
San Diego, CA 92101

- 6998
(619) 557-5620

Matters of company fraud are usually investigated by the Federal Trade Commission. They can be contacted at the following:

Northeast Region Federal Trade Commission 1 Bowling Green New York, NY 10004.

For Consumer Complaints contact the Consumer Response Center:

By phone: toll free 877-FTC-HELP (382-4357); 9:00 am to 5:00 pm Eastern Standard Time, Monday through Friday;

 

By mail: Consumer Response Center, Federal Trade Commission, 600 Pennsylvania Ave, NW, Washington, DC 20580

Information on Immune Response Biophama is as follows:

CERTIFICATE OF INCORPORATION

State of Delaware

Secretary of State

Division of Corporations

Delivered 01:28 PM 06/20/2011

FILED 12:27 PM 06/20/2011

SRV 110739145 - 4999105 FILE

Immune Response BioPharma, Inc.

244 5th Avenue Suite 1727

New York City, NY 10001 U.S.A.

(917) 275-7931

Recent appointments at Immune Response Biopharma

At one time David Buswell said the the former executives at Immune Response Inc. aka Orchestra Therapeutic caused the companies failure and not the research. I find it interesting that now many of those some people are members of the new Immune Response BioPharma. My belief is that these are the people behind Immune Response Biopharma and that they deliberately caused the company to go bankrupt in order to take the research and start a new company called Immune Response BioPharma so they could dump all the previous investors, start a new company, and reap all the profits for themselves. I suspect it is only a matter of time till we hear that Kevin Kimberlin and Spencer Trask are now involved in the new Immune Response BioPharma.

Boards and new Advisors at Immune Response Biophama

It appears that many of the people who were previously involved in Immune Response Corporation and Orchestra Therapeutics are now joining Immune Response BioPharma. This proves my belief that the original companies research was stolen and the company itself manipulated into backruptcy so that a new company could be formed and the previous investors dumped and cheated out of their investments. Basically what has happened is that Kevin Kimberlin and Spencer Trask and the rest of the people who were at Immune Response Corp. manipulated the company so that they could change the name to Orchestra Theraputics and then purchase all the intellectural property rights to the research. They then manipulated the company into bankruptcy so they could dump all the original investors. Now they are starting a new company claming that have all the rights to the research funded by investors for over twenty years through Immune Response and Orchestra Thera. All the original crooks that were running Orchestra at the end will end up back in leadership roles with this new Immune Response Biopharma where they will cash in on the research while cheating the original investors out of everything. Typical Wall Street maneuver to make make as much profit as you can for yourself.

Open letter to Editors on Immune Response BioPharma

I have begun sending out letters to various publications seeking an investigative report into the actions of Immune Response BioPharma and the original Immune Response Inc/Orchestra Therapeutic.

Editor 

Dear Sir or Madam:

I am writing to suggest a story that your publication might find interesting enough to pursue.  I am a long time investor in a company called Orchestra Therapeutic Corporations Inc. The company began under the name Immune Response Inc.(IMNR) in the 1980s under Jonas Salk and Kevin Kimberlin with Spencer Trask to find a cure for aids, rheumatoid arthritis, psoriasis, and other diseases. Orchestra Therapeutic now trades under the symbol OCHTQ after going through a bankruptcy.  

Recently another research company called Immune Response BioPharma was created under the leadership of David Buswell. This company now claims to own all the intellectual property and research rights of  Immune Response/Orchestra Therapeutic saying that the research was legally abandoned. When I contacted Eric Swanson Communications Officer at Immune Response Biophrma he replied with the following:
"Per your note to Mr. Buswell, it's my understanding you have issues relating to his medical and business efforts. While I'm not a brankruptcy expert, I believe the science he has embraced was abandoned by the parties you mentioned in your email. It seems to me he's trying to make good on something that was left to the trash collectors." and that what they found was “in the trash can.” Recently David Buswell the company’s CEO has said in released statements, “REMUNE is a winner hands down and see the vaccine as the gold standard of treatment, eventually 90% market share.” 

It seems a little hard to believe that scientific research involving clinical trials involving patients could be retrieved from a trash can and that this same research could then turn out to be a gold mine. Investors holding shares in Orchestra/Immune Response like myself are concerned that the original Immune Response’s operations were handled in such a way as to force a bankruptcy so that the research could then be transferred to another company where it could then be reissued as an IPO thus abandoning the original investors. I have written numerous letters and E-mails to Kevin Kimberlin and Spencer Trask asking if there was any connection between them and the new Immune Response BioPharma, but they have refused to reply as has David Buswell.

In fact the only response I have been able to obtain from David Buswell was in the form of threats such as the following:

“I would ask you to respect the rule of law and cease and desist from contacting, harassing, interference of business, fraud, manipulation, slander, defamation, illegal activities, written or oral communication threathening, harming, cyber attacks, physical or oral or via mail any blackmail or greenmail activities or otherwise prohibited illegal activities against Immune Response BioPharma or its employees, founders or members in any shape form or fashion will be deemed as hostile acts and reported to the proper authorities. Immune Respone BioPharma is a peaceful company only seeking to save lives and has its own pipeline of life saving drugs and will act responsibly by developing those therapeutic treatments in the of mankind. Should you continue with your course of actions it will become a criminal matter which the proper authorities will be notified, at this time Immune Response BioPharma will not pursue any legal actions but cautions you to refrain from further activities that would otherwise violate the rule of law. Mr. Reese make no mistake you will be held accountable should you continue to harrass, impede, threathen, blackmail, interfere with our business and notify the Department of Justice and the FBI should you send more harrassing emails. Please Cease & Desist as of 2/24/2011 your activities and contact with Immune Response BioPharma, should you violate this order appropriate legal action will be taken. Immune Response BioPharma will use any and all legal avenues civil and criminal to halt any violations of this order.

Sincerely, Immune Response BioPharma Legal Department”

It seems the new Immune Response has not only tried to take over the research, but also the name Immune Response and has started a new unit called,(you guessed it) Orchestra Therapeutics. It claims Orchestra Therapeutics will focus on the development of new antibiotics and manufacturing of Generic antibiotics.

Obviously, for the legal rights of the original stockholders to have been abandoned legally there could be no involvement in Immune Response BioPharma by either Mr. Kimberlin or Spencer Trask as that would simply mean that they helped finance and start a new company under a new name and simply transferred the research rights in order to abandon the previous companies investors and make more profit for themselves.

I would like to encourage your publication to investigate the new Immune Response BioPharma and how this company is conducting its business in light of the information you now have. I could make for a very interesting story in light of the connection with Jonas Salk and the renewed attention that Aids research is now receiving.

Immune Response and Orchestra stock manipulation

The price of Orchestra Therapeutics stays at 0.0035. Twice in the past few weeks including last week I purchased shares in of the stock at the market price which was .01 cents a share bringing the last purchase price up to .01 cents on the financial board. Both times there was an immediate trade of over 300 shares at 0.0035 bringing the price of the stock back down. Could it be that someone is purposely trying to manipulate the price of the stock to keep it below .01 cents a share. I mean why would someone offer to sell at 0.0035 when the last trade was higher and why would it always be the same price and the same amount of stock being exchanged. I wounder if someone is not deliberately trying to keep the price down at 0.0035 Does anyone have a guess as to what reason they might have?            

Orchestra Therapeutics and Immune Response BioPharma

The so called new Immune Response BioPharma company that claims to now own the research from Immune Response/Orchestra Therapeutics has now annouced that it has started a new unit called,(you guessed it) Orchestra Therapeutics. It claims Orchestra Therapeutics will focus on the development of new antibiotics and manufacturing of Generic antibiotics. Can you believe that? First they claim to be a whole new company and call themselves Immune Response BioPharma. Only this so called new company's claim to fame is the fact that they say they now own the rights to all the research of another company by the name of (you guessed it) Immune Response Corporation. Now they claim to be starting a new unit by the name of (you guessed it again) Orchestra Therapeutics which just happens to be the name that Immune Response Corporation changed to and still trades under as OCHTQ.PK. Apparently the primary goal of David Buswell and his accomplices is too not only steal the research financed by the investors in IMNR/OCHTQ.PK, but also to steal the names as well. I can't figure out if they know they are running a scam and aren't worried about the long term outcome of their actions or if they think that investors will be so blind as to not see that these companies are all one and the same. The only thing different is that insiders have tried to manipulate the original companies so that they could cheat the original investors, steal the research, and make all the profits.

Immune Response BioPharma Stock

I purchased another 3000 shares of Orchestra Theraputic (OCHTQ.PK) today. It is important that stock holders in Immune Response/Orchestra Therap keep the stock active to help protect our rights and to make sure it stays active on the trading boards.

Immune Response Biopharma and Rheumatoid Arthritis

I have a sister and a best friend who suffer from Rheumatoid arthritis. It is the reason I invested in the company to begin with. I wonder if David Buswell and Immune Response Biopharma "found" that research abandoned somewhere also and now say it is theirs.

"The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received United States Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, RAVAX(TM). The recently issued patent has specific claims covering immunization utilizing DNA vaccines that are designed to synthesize the T cell receptor (TCR) Vbeta specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key "superantigen" protein sequences from the Vbeta 3, Vbeta 14 and Vbeta 17 regions of the TCR present on the surface of these pathogenic T cells thought to be associated with rheumatoid arthritis. The Company believes that vaccination with RAVAX may inhibit the disease-associated T cells that cause rheumatoid arthritis, and prevent further damage in patients suffering from the disease. "This recent issuance is a key patent in that it extends previous coverage related to the delivery and composition of RAVAX to now include DNA vaccines in addition to peptide vaccines," said Richard Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. "DNA vaccination is proving to be an effective method of inducing immunity against a number of human diseases. The issuance of this patent to include DNA vaccination for our peptide vaccine program serves to further strengthen our intellectual property position in the field of T cell receptor vaccine research." The Company previously announced that it was issued U.S. patent number 6,090,387 for vaccinating with T cell receptor peptides on August 9, 2000. Several autoimmune disorders, including rheumatoid arthritis, psoriasis and multiple sclerosis, are thought to result in part from the proliferation of "autoreactive pathogenic T cells," immune cells that incorrectly identify the body's own cells as foreign and destroy them. The Immune Response Corporation has completed two Phase II clinical trials in rheumatoid arthritis using their proprietary immune-based therapy based on TCR peptide vaccines. In a phase IIb trial of 340 rheumatoid arthritis patients, RAVAX demonstrated safety and tolerability, and suggested a statistically significant treatment effect at one time point after the third injection using criteria established by the American College of Rheumatology (ACR 20). The ACR 20 criteria require an improvement in tender and swollen joint counts of at least 20% from baseline, along with improvement in three of five other disease-related criteria. To date, no clinical studies have been initiated utilizing the DNA vaccination approach."

Immune Response BioPharma and investors

Immune Response BioPharma's David Buswell made some interesting comments recently in regards to House Resolution 1179 (H. Res 1179)  saying that it was wasted taxpayer dollars. He seems to take the moral high ground in the following statements.

“These are really wicked bad people and want to waste your taxpayer dollars on obsolete and junk science. Everyone knows the way to defeat a virus is through the weakened vaccine. They are terrified of my efforts to get REMUNE approved and have gone so far as to trick me on to a conference call and both of them yelled at me for over two hours. These people are crazy and just want to go on needless conferences wasting your taxpayer dollars and junk science and toxic solutions. I pray that God takes action against these evil people”

“They have done their best to discredit my efforts and are trying their best to derail patients from getting the REMUNE vaccine. REMUNE can solve the majority of the HIV/AIDS issues. And I am not afraid of these people they are cowards who do not want a real solution to the pandemic. They just want to continue their lifestyles of wasting taxpayer dollars, and big pharma too has no reason to want REMUNE approved they lose billions of dollars. I restarted Immune Response to save lives I receive no salary. The IP and trademarks were abandoned the company was dissolved and I restarted this company because I believe the science is sound and I won’t be pushed around by wall St.. or these evil people. I am not afraid of cowards”

I would suggest that the best way to advance the research conducted by Immune Response Corportation and Orchestra Therapeutics (OCHT) is to honor the shareholders of OCHT which still trades and whose investors still have rights. The people in charge of managing IMNR and OCHT might have been dishonest, but their investors were hard working people who invested in what they thought was an honestly operated company. Immune Response BioPharma should recognize the shareholders in OCHT by giving them stock in their new company or else paying them compensation for their investments which created the research David Buswell is now trying to bring to market. If you are going to take research from a company that had a reputation for trying to prevent negative test results from being printed not to mention the management disaster that was Immune Response/Orchestra then you better start out on the right foot and do it in a fair and honest manner from day one.